- Home
- REGN vs APO Comparison
REGN vs APO Comparison
Compare REGN & APO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- APO
- Stock Information
- Founded
- REGN 1988
- APO 1990
- Country
- REGN United States
- APO United States
- Employees
- REGN N/A
- APO N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- APO Investment Managers
- Sector
- REGN Health Care
- APO Finance
- Exchange
- REGN Nasdaq
- APO Nasdaq
- Market Cap
- REGN 110.0B
- APO 98.9B
- IPO Year
- REGN 1991
- APO 2011
- Fundamental
- Price
- REGN $701.85
- APO $171.10
- Analyst Decision
- REGN Buy
- APO Buy
- Analyst Count
- REGN 24
- APO 22
- Target Price
- REGN $1,054.00
- APO $159.33
- AVG Volume (30 Days)
- REGN 920.8K
- APO 9.8M
- Earning Date
- REGN 01-31-2025
- APO 02-06-2025
- Dividend Yield
- REGN N/A
- APO 1.08%
- EPS Growth
- REGN 15.31
- APO 94.60
- EPS
- REGN 40.43
- APO 9.42
- Revenue
- REGN $13,847,100,000.00
- APO $31,671,000,000.00
- Revenue This Year
- REGN $10.20
- APO N/A
- Revenue Next Year
- REGN $4.16
- APO $17.02
- P/E Ratio
- REGN $17.36
- APO $18.15
- Revenue Growth
- REGN 5.72
- APO 22.97
- 52 Week Low
- REGN $693.00
- APO $89.76
- 52 Week High
- REGN $1,211.20
- APO $189.49
- Technical
- Relative Strength Index (RSI)
- REGN 27.80
- APO 52.47
- Support Level
- REGN $693.00
- APO $166.45
- Resistance Level
- REGN $745.00
- APO $178.11
- Average True Range (ATR)
- REGN 21.29
- APO 5.85
- MACD
- REGN 0.05
- APO -1.73
- Stochastic Oscillator
- REGN 8.20
- APO 20.18
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
About APO Apollo Global Management Inc. (New)
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Asset Management, Retirement Services, and Principal Investing. It generates maximum revenue from the Retirement Services segment.